Importance of Testing for ROS1 Rearrangements in Non-Small Cell Lung Cancer in the Era of Targeted Therapy in a Latin American Country

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;2:1–41.
   Google Scholar
• de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503–513. doi:10.1056/NEJMoa1911793
   PubMed Web of Science ®Google Scholar
• Howlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640–649. doi:10.1056/NEJMoa1916623
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013;340(6127):1546–1558. doi:10.1126/science.1235122
   Google Scholar
• Swanton C, Govindan R, Longo DL. Clinical implications of genomic discoveries in lung cancer. N Engl J Med. 2016;374(19):1864–1873. doi:10.1056/NEJMra1504688
   PubMed Web of Science ®Google Scholar
• Reck M, Rabe KF, Longo DL. Precision diagnosis and treatment for advanced non–small-cell lung cancer. N Engl J Med. 2017;377(9):849–861. doi:10.1056/NEJMra1703413
   PubMed Web of Science ®Google Scholar
• Yang J, Pyo JS, Kang G. Clinicopathological significance and diagnostic approach of Ros1 rearrangement in non-small cell lung cancer: a meta-analysis: ros1 in non-small cell lung cancer. Int J Biol Markers. 2018;33(4):520–527. doi:10.1177/1724600818772194
   Web of Science ®Google Scholar
• Zhu Q, Zhan P, Zhang X, Lv T, Song Y. Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2015;4(3):300–309. doi:10.3978/j.issn.2218-6751.2015.05.01
   PubMedGoogle Scholar
• Lin JJ, Ritterhouse LL, Ali SM, et al. ROS1 fusions rarely overlap with other oncogenic drivers in non–small cell lung cancer. J Thorac Oncol. 2017;12(5):872–877. doi:10.1016/j.jtho.2017.01.004
   PubMed Web of Science ®Google Scholar
• Park S, Ahn BC, Lim SW, et al. Characteristics and outcome of ROS1-positive non–small cell lung cancer patients in routine clinical practice. J Thorac Oncol. 2018;13(9):1373–1382. doi:10.1016/j.jtho.2018.05.026
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wang W, Xu C, et al. A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib. Cancer Biol Ther. 2018;19(12):1097–1101. doi:10.1080/15384047.2018.1491506
   PubMed Web of Science ®Google Scholar
• Cha YJ, Lee JS, Kim HR, et al. Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. PLoS One. 2014;9(7):1–10. doi:10.1371/journal.pone.0103333
   Web of Science ®Google Scholar
• Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18(16):4449–4457. doi:10.1158/1078-0432.CCR-11-3351
   PubMed Web of Science ®Google Scholar
• Conde E, Hernandez S, Martinez R, et al. Assessment of a new ROS1 Immunohistochemistry Clone (SP384) for the identification of ROS1 rearrangements in patients with non–small cell lung carcinoma: the ROSING study. J Thorac Oncol. 2019;14(12):2120–2132. doi:10.1016/j.jtho.2019.07.005
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors guideline from the college of American pathologists, the international association for the study of lung cancer, and the a. Arch Pathol Lab Med. 2018;142(3):321–346. doi:10.5858/arpa.2017-0388-CP
   PubMed Web of Science ®Google Scholar
• Pavlakis N, Cooper C, John T, et al. Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. Pathology. 2019;51(7):673–680. doi:10.1016/j.pathol.2019.08.006
   PubMed Web of Science ®Google Scholar
• Of IA. IASLC Atlas of ALK and ROS1 Testing in Lung Cancer. FL: North Fort Myers; 2016. Available from: https://www.iaslc.org/research-education/publications-resources-guidelines/iaslc-atlas-alk-and-ros1-testing-lung-cancer. Accessed July 8, 2024.
   Google Scholar
• Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971. doi:10.1056/NEJMoa1406766
   PubMed Web of Science ®Google Scholar
• Mazières J, Zalcman G, Crinò L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol. 2015;33(9):992–999. doi:10.1200/JCO.2014.58.3302
   PubMed Web of Science ®Google Scholar
• Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30(7):1121–1126. doi:10.1093/annonc/mdz131
   PubMed Web of Science ®Google Scholar
• Conde E, Rojo F, Gómez J, et al. Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing. J Clin Pathol. 2021. doi:10.1136/jclinpath-2021-207490
   PubMed Web of Science ®Google Scholar
• Pisapia P, Pepe F, Sgariglia R, et al. Methods for actionable gene fusion detection in lung cancer: now and in the future. Pharmacogenomics. 2021;22(13):833–847. PMID: 34525844. doi:10.2217/pgs-2021-0048
   PubMed Web of Science ®Google Scholar
• Malapelle U, Muscarella LA, Pisapia P, Rossi A. Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward. Expert Opin Investig Drugs. 2020;29(4):363–372. PMID: 32073317. doi:10.1080/13543784.2020.1732922
   PubMed Web of Science ®Google Scholar
• Muminovic M, Carracedo Uribe CR, Alvarez-Pinzon A, Shan K, Raez LE. Importance of ROS1 gene fusions in non-small cell lung cancer. Cancer Drug Resist. 2023;6(2):332–344. PMID: 37457125; PMCID: PMC10344718. doi:10.20517/cdr.2022.105
   PubMedGoogle Scholar
• Pisapia P, Lozano MD, Vigliar E, et al. ALK and ROS1 testing on lung cancer cytologic samples: perspectives. Cancer Cytopathol. 2017;125(11):817–830. PMID: 28743163. doi:10.1002/cncy.21899
   PubMed Web of Science ®Google Scholar
• Bergethon K, Shaw AT, Ou SH. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–870. doi:10.1200/JCO.2011.35.6345
   PubMed Web of Science ®Google Scholar
• Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012;18(17):4570–4579. doi:10.1158/1078-0432.CCR-12-0550
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wu C, Ding W, et al. Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer. Thorac Cancer. 2019;10(1):47–53. doi:10.1111/1759-7714.12899
   PubMed Web of Science ®Google Scholar
• Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials [published correction appears in Lancet Oncol. 2020 Feb;21(2):e70] [published correction appears in Lancet Oncol. 2020 Jul; 21(7):e341]. Lancet Oncol. 2020;21(2):261–270. doi:10.1016/S1470-2045(19)30690-4
   PubMed Web of Science ®Google Scholar
• Lim SM, Kim HR, Lee JS, et al. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol. 2017;35(23):2613–2618. doi:10.1200/JCO.2016.71.3701
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global Phase 2 study. Lancet Oncol. 2018;19(12):1654–1667. doi:10.1016/S1470-2045(18)30649-1
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncol. 2019;20(12):1691–1701. doi:10.1016/S1470-2045(19)30655-2
   PubMed Web of Science ®Google Scholar
• Cho BC, Lin J. Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC). Eur J Cancer. 2022;15(16):30. doi:10.1016/S0959-8049(22)00812-7
   Google Scholar
• Wu YL, Yang JC, Kim DW, et al. Phase II study of Crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(14):1405–1411. doi:10.1200/JCO.2017.75.5587
   PubMed Web of Science ®Google Scholar
• Moro-Sibilot D, Cozic N, Pérol M, et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Ann Oncol. 2019;30(12):1985–1991. doi:10.1093/annonc/mdz407
   PubMed Web of Science ®Google Scholar
• Sahu A, Prabhash K, Noronha V, Joshi A, Desai S. Crizotinib: a comprehensive review. South Asian J Cancer. 2013;2(2):91–97. doi:10.4103/2278-330X.110506
   PubMedGoogle Scholar
• Chiari R, Ricciuti B, Landi L, et al. ROS1-rearranged non-small-cell lung cancer is associated with a high rate of venous thromboembolism: analysis from a phase II, Prospective, Multicenter, Two-arms Trial (METROS). Clin Lung Cancer. 2020;21(1):15–20. doi:10.1016/j.cllc.2019.06.012
   PubMed Web of Science ®Google Scholar
• Muñoz-Unceta N, Zugazagoitia J, Manzano A, et al. High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1. Eur J Cancer. 2020;141:193–198. doi:10.1016/j.ejca.2020.10.002
   PubMed Web of Science ®Google Scholar